Lung Cancer Genomic Screening Project for Individualized Medicine in Japan

Lung Cancer Genomic Screening Project for Individualized Medicine in Japan - LC-SCRUM-Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010234

Enrollment

6500

Registered

2013-03-13

Start date

2013-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically diagnosed NSCLC 2. Clinical stage II, III or IV 3. Eastern Cooperative Oncology Group performance status (PS) of 0 or 1 4. Adequate function of main organ that meets the following criteria -1 Neutrophil count>=1500/mm3 -2 Hemoglobin>=8.0g/dL -3 Platelet count>=7.5*104/mm3 -4 AST,ALT<=upper limit of normal *2.5 5 Serum bilirubin <=upper limit of normal *1.5 mg/dL 5. Other serious medical complications (interstitial pneumonitis, uncontrolled diabetes mellitus, heart failure, active infectious disease etc.) 6. Life expectancy more than 3 months 7. Materials available for genome analysis 8. Declaring enrollement of clinical trial through genome analysis 9. Written informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To clarify the clinicopathological and molecular feature in RET fusion-positive lung cancer	—

Countries

Japan

Contacts

Public ContactKoichi Goto

National Cancer Center Hospital East Division of Thoracic Oncology

kgoto@east.ncc.go.jp04-7133-1111

Outcome results